Cargando…

Metabolic biomarkers of risperidone-induced weight gain in drug-naïve patients with schizophrenia

BACKGROUND: Risperidone is a commonly prescribed antipsychotic drug with a potential side effect of weight gain. However, the pathophysiological mechanism is still poorly understood. Here, we sought to identify potential biomarkers of risperidone-induced weight gain by using a targeted metabolomics...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiu, Yuying, Dong, Yeqing, Sun, Wei, Li, Gang, Li, Mei Juan, Zhao, Yongping, Jiang, Changyong, Li, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171109/ https://www.ncbi.nlm.nih.gov/pubmed/37181896 http://dx.doi.org/10.3389/fpsyt.2023.1144873

Ejemplares similares

C677T Polymorphism in the MTHFR Gene Is Associated With Risperidone-Induced Weight Gain in Schizophrenia
por: Liao, Jingping, et al.
Publicado: (2020)

Striatum-related spontaneous coactivation patterns predict treatment response on positive symptoms of drug-naive first-episode schizophrenia with risperidone monotherapy
por: Zong, Xiaofen, et al.
Publicado: (2023)

Antioxidant Enzymes and Weight Gain in Drug-naive First-episode Schizophrenia Patients Treated with Risperidone for 12 Weeks: A Prospective Longitudinal Study
por: Liu, Haixia, et al.
Publicado: (2022)

Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study
por: Hori, Hikaru, et al.
Publicado: (2018)

Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients
por: Aquino, Adriano, et al.
Publicado: (2018)

The Association Between Cognitive Deficits and Clinical Characteristic in First-Episode Drug Naïve Patients With Schizophrenia
por: Peng, Xing-Jie, et al.
Publicado: (2021)

Influence of EGR3 Transfection on Imaging and Behavior in Rats and Therapeutic Effect of Risperidone in Schizophrenia Model
por: Li, Guangfei, et al.
Publicado: (2020)

Association Study of KCNH7 Polymorphisms and Individual Responses to Risperidone Treatment in Schizophrenia
por: Wang, Xueping, et al.
Publicado: (2019)

Corrigendum: The Association Between Cognitive Deficits and Clinical Characteristic in First-Episode Drug Naïve Patients With Schizophrenia
por: Peng, Xing-Jie, et al.
Publicado: (2021)

Corrigendum: The association between cognitive deficits and clinical characteristic in first-episode drug naïve patients with schizophrenia
por: Peng, Xing-Jie, et al.
Publicado: (2022)

Identification of Plasma Biomarkers in Drug-Naïve Schizophrenia Using Targeted Metabolomics
por: Su, Qiao, et al.
Publicado: (2023)

The Role of Butyric Acid in Treatment Response in Drug-Naïve First Episode Schizophrenia
por: Li, Xue, et al.
Publicado: (2021)

Comparison of olanzapine-induced weight gain and metabolism abnormalities between topiramate and vitamin C in patients with schizophrenia: a preliminary study
por: Zhang, Jinling, et al.
Publicado: (2023)

Abnormalities of Electroencephalography Microstates in Drug-Naïve, First-Episode Schizophrenia
por: Sun, Qiaoling, et al.
Publicado: (2022)

Worth the Weight? Olanzapine Prescribing in Schizophrenia. A Review of Weight Gain and Other Cardiometabolic Side Effects of Olanzapine
por: Fitzgerald, Ita, et al.
Publicado: (2021)

Risperidone Effects on Brain Dynamic Connectivity—A Prospective Resting-State fMRI Study in Schizophrenia
por: Lottman, Kristin K., et al.
Publicado: (2017)

Risperidone-Associated Neuroleptic Malignant Syndrome in an Inpatient With Schizophrenia, With Successful Rechallenge and 3 Year Follow-Up
por: Chen, Ting-Ren, et al.
Publicado: (2018)

Unveiling the Metabolic Profile of First-Episode Drug-Naïve Schizophrenia Patients: Baseline Characteristics of a Longitudinal Study Among Han Chinese
por: Zhang, Qi, et al.
Publicado: (2021)

Abnormal Brain Network Interaction Associated With Positive Symptoms in Drug-Naive Patients With First-Episode Schizophrenia
por: Yuan, Liu, et al.
Publicado: (2022)

The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children
por: Libowitz, Mark R., et al.
Publicado: (2021)

Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia
por: Song, Xueqin, et al.
Publicado: (2014)

Deciphering Risperidone-Induced Lipogenesis by Network Pharmacology and Molecular Validation
por: Fu, Yun, et al.
Publicado: (2022)

RISPERIDONE IN SCHIZOPHRENIA
por: Agashe, Mohan, et al.
Publicado: (1999)

RISPERIDONE IN SCHIZOPHRENIA
por: Kumar, P.N. Suresh
Publicado: (1999)

Insulin Resistance and Oxidative Stress: In Relation to Cognitive Function and Psychopathology in Drug-Naïve, First-Episode Drug-Free Schizophrenia
por: Tao, Qi, et al.
Publicado: (2020)

Reduced Brain Activity in the Right Putamen as an Early Predictor for Treatment Response in Drug-Naive, First-Episode Schizophrenia
por: Wu, Renrong, et al.
Publicado: (2019)

Aberrant Functional Connectivity of the Orbitofrontal Cortex Is Associated With Excited Symptoms in First-Episode Drug-Naïve Patients With Schizophrenia
por: Chen, Congxin, et al.
Publicado: (2022)

Risperidone-Induced Sexual Dysfunction Case Report
por: Cichon, Gregory J, et al.
Publicado: (2023)

Anterior Cingulate Cortex Glutamate Levels Are Related to Response to Initial Antipsychotic Treatment in Drug-Naive First-Episode Schizophrenia Patients
por: Li, Jinguang, et al.
Publicado: (2020)

Incidence and factors associated of early non-response in first-treatment and drug-naïve patients with schizophrenia: a real-world study
por: Zhang, Lin, et al.
Publicado: (2023)

Effect Of Risperidone And Olanzapine On The Metabolic Profile Of Drug Naïve Bipolar Disorder Patients.
por: Gupta, Gajal, et al.
Publicado: (2022)

Risperidone Induced Hyperprolactinemia: From Basic to Clinical Studies
por: Stojkovic, Milena, et al.
Publicado: (2022)

Pathophysiology and management of risperidone-induced sialorrhea: case report
por: Torrico, Tyler, et al.
Publicado: (2023)

Association Between Depressive Symptoms and Serum Brain-Derived Neurotrophic Factor Levels in Patients With First-Episode and Drug-Naïve Schizophrenia
por: Wu, Yuxuan, et al.
Publicado: (2022)

The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain
por: Li, Li, et al.
Publicado: (2021)

A double-blind randomized trial between risperidone and haloperidol in drug-naive patients with paranoid schizophrenia
por: Sagar, K.J. Vijay, et al.
Publicado: (2005)

Metabolic Barriers to Weight Gain in Patients With Anorexia Nervosa: A Young Adult Case Report
por: Haas, Verena, et al.
Publicado: (2018)

The Relationship Between Abnormal Resting-State Functional Connectivity of the Left Superior Frontal Gyrus and Cognitive Impairments in Youth-Onset Drug-Naïve Schizophrenia
por: Qiu, Xiaolei, et al.
Publicado: (2021)

Cognitive dysfunction and cortical structural abnormalities in first-episode drug-naïve schizophrenia patients with auditory verbal hallucination
por: Shen, Xuran, et al.
Publicado: (2022)

Dysfunction of Resting-State Functional Connectivity of Amygdala Subregions in Drug-Naïve Patients With Generalized Anxiety Disorder
por: Wang, Mei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5lvcuaeur1pu7d6g7f1le0qn48